Pacific Biosciences of California, Inc. (PACB)

NASDAQ | Biotech | Genomic sequencing technology
Intro rate Introductory pricing for early customers through June 30 — the same full analysis at a lower rate while we refine delivery.
Free
No email, no account, no signup.
Pulling latest news for Pacific Biosciences of California, Inc.…
Bull
Bear
Intro rate Introductory pricing for early customers through June 30 — the same full analysis at a lower rate while we refine delivery.

Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.

Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report – $4.99 $1.25
Order analysis – $4.99 $1.25

Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.

Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Genomic sequencing technology
Market Cap
$410M
We're already tracking Pacific Biosciences of California, Inc. — here are the latest events we've registered

Recent News

  • On May 7, 2026, the company reported first-quarter revenue of $37.2 million, which was flat year-over-year but missed analyst estimates. Alongside the results, it announced the completion of an asset sale to Illumina for $48.1 million to focus on its core long-read technology. The company also narrowed its full-year 2026 revenue guidance to a range of $165 million to $175 million.
Want to know how this news affects Pacific Biosciences of California, Inc.? Order the analysis.
Order analysis – $4.99 $1.25

What you get

A complete express analysis — not just a signal. Delivered as a webpage in your account.

  • Signal: BUY / HOLD / SELL — with clear reasoning
  • Sentiment score 1–10 based on news, reports, and market data
  • Risk score 1–10 (dilution, jurisdiction, execution)
  • Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
  • Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
  • Upcoming catalysts with dates
  • Sources: news, filings, market data, and investor forums
  • Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Pacific Biosciences of California, Inc. will be delivered in the same format.
Order analysis – $4.99 $1.25
Not satisfied? Get your money back within 7 days — no questions asked.
Pacific Biosciences of California, Inc. (PACB)
Fresh analysis on demand
Buy express analysis – $4.99 $1.25
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.